Eun Sook Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eun Sook Hwang has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Mi Gyeong Jeong
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, South Korea
22 shared publicationsHyo Kyeong Kim
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
15 shared publicationsHee Yeon Won
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
14 shared publicationsEun Jung Jang
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
12 shared publications- Jeong-Ho Hong
Division of Life Sciences, Korea University, Seoul, Korea
12 shared publications Hana Jeong
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
11 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 52067
Context-Dependent Modulation of Macrophage Plasticity by Cordycepin Drives Tumor Regression in Melanoma
Background and Aim: Cordycepin (CDC), an adenosine (ADO) analog from Cordyceps mushrooms, exhibits potent anti-tumor and immunomodulatory activities. However, the precise mechanisms governing its effects on macrophage plasticity remain poorly understood. This study aimed to isolate CDC from a high-yielding Cordyceps cultivar, validate its systemic anti-tumor efficacy, and elucidate the mechanobiological cues regulating CDC-driven macrophage functions under varying cell-density states. Experimental Procedure: CDC (>98% purity) was isolated and structurally characterized via nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). Primary bone marrow-derived macrophages and RAW264.7 cells, cultured under sparse (~30%) or confluent (100%) conditions, were treated with CDC or ADO. We evaluated cell viability, pro-inflammatory cytokine expression, and Nuclear Factor kappa B (NF-κB) p65 signaling, phagocytosis, and migration. The therapeutic potential of CDC-primed macrophages was assessed via in vitro melanoma co-culture and in vivo intratumoral adoptive transfer in B16F10 tumor-bearing mice. Key Results: Systemic administration of CDC significantly inhibited melanoma growth in vivo, promoting apoptosis, enhancing macrophage infiltration. We discovered that CDC regulates macrophage functions via a density-dependent “switch”: while CDC induced cytotoxicity in sparse cultures, it significantly augmented M1-like cytokine production in confluent states without compromising viability. This density-dependent activation was mediated by the A2A adenosine receptor (A2AR), triggering the Akt–NF-κB p65 signaling axis. Furthermore, CDC upregulated migration- and phagocytosis-associated genes, enhancing tumor cell clearance. Notably, intratumoral injection of CDC-primed macrophages markedly reduced tumor volume and size in vivo. Conclusions and Implications: CDC modulates macrophage activation through a unique mechanobiological switch. Under high-density conditions—mimicking the dense tumor microenvironment—CDC enhances A2AR-mediated NF-κB activation, boosting macrophage activation, recruitment, and phagocytosis to facilitate tumor regression. These findings establish CDC as a context-dependent immunomodulator capable of reprogramming macrophages toward a tumoricidal phenotype.
- 27 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 52067
Open AccessContext-Dependent Modulation of Macrophage Plasticity by Cordycepin Drives Tumor Regression in Melanoma
Background and Aim: Cordycepin (CDC), an adenosine (ADO) analog from Cordyceps mushrooms, exhibits potent anti-tumor and immunomodulatory activities. However, the precise mechanisms governing its effects on macrophage plasticity remain poorly understood. This study aimed to isolate CDC from a high-yielding Cordyceps cultivar, validate its systemic anti-tumor efficacy, and elucidate the mechanobiological cues regulating CDC-driven macrophage functions under varying cell-density states. Experimental Procedure: CDC (>98% purity) was isolated and structurally characterized via nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). Primary bone marrow-derived macrophages and RAW264.7 cells, cultured under sparse (~30%) or confluent (100%) conditions, were treated with CDC or ADO. We evaluated cell viability, pro-inflammatory cytokine expression, and Nuclear Factor kappa B (NF-κB) p65 signaling, phagocytosis, and migration. The therapeutic potential of CDC-primed macrophages was assessed via in vitro melanoma co-culture and in vivo intratumoral adoptive transfer in B16F10 tumor-bearing mice. Key Results: Systemic administration of CDC significantly inhibited melanoma growth in vivo, promoting apoptosis, enhancing macrophage infiltration. We discovered that CDC regulates macrophage functions via a density-dependent “switch”: while CDC induced cytotoxicity in sparse cultures, it significantly augmented M1-like cytokine production in confluent states without compromising viability. This density-dependent activation was mediated by the A2A adenosine receptor (A2AR), triggering the Akt–NF-κB p65 signaling axis. Furthermore, CDC upregulated migration- and phagocytosis-associated genes, enhancing tumor cell clearance. Notably, intratumoral injection of CDC-primed macrophages markedly reduced tumor volume and size in vivo. Conclusions and Implications: CDC modulates macrophage activation through a unique mechanobiological switch. Under high-density conditions—mimicking the dense tumor microenvironment—CDC enhances A2AR-mediated NF-κB activation, boosting macrophage activation, recruitment, and phagocytosis to facilitate tumor regression. These findings establish CDC as a context-dependent immunomodulator capable of reprogramming macrophages toward a tumoricidal phenotype.
- Open Access
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1755268
PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue
This study aimed to identify small molecules that inhibit the binding of the SARS-CoV-2 Spike protein to its host receptor, angiotensin-converting enzyme 2 (ACE2), without impairing the enzymatic activity of ACE2. Such inhibitors may support the development of broad-spectrum antivirals and therapeutic strategies for emerging SARS-CoV-2 variants. Through extensive screening using both cell-free and cell-based assays, we identified phenoxy-methylaniline (PoMA) compounds as effective inhibitors of the SARS-CoV-2 Spike-ACE2 interaction. Among these, PoMA-10, featuring trifluoromethoxy and dimethylaniline moieties, exhibited the most potent inhibitory activity while preserving ACE2 enzymatic function. Computational modeling predicted direct binding of PoMA-10 to ACE2, which was corroborated by protein mobility shift assays. This was further substantiated by surface plasmon resonance analysis and molecular dynamics simulations, which confirmed the stable binding of PoMA-10 at an interface-adjacent site on ACE2 and the disruption of SARS-CoV-2 Spike–ACE2 interaction. In Vero cells, PoMA-10 significantly reduced infection by ancestral SARS-CoV-2 and the Delta and Gamma variants. Moreover, PoMA-10 alleviated lung epithelial cell damage and protected against lipopolysaccharide-induced lung injury in vivo . These findings demonstrate that PoMA-10 functions as a dual-action inhibitor blocking viral entry and protecting against lung injury, and highlight its potential as a therapeutic candidate in the management of COVID-19 and related pulmonary complications.
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1755268
Open AccessPoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike–ACE2 interaction and protecting lung tissue
This study aimed to identify small molecules that inhibit the binding of the SARS-CoV-2 Spike protein to its host receptor, angiotensin-converting enzyme 2 (ACE2), without impairing the enzymatic activity of ACE2. Such inhibitors may support the development of broad-spectrum antivirals and therapeutic strategies for emerging SARS-CoV-2 variants. Through extensive screening using both cell-free and cell-based assays, we identified phenoxy-methylaniline (PoMA) compounds as effective inhibitors of the SARS-CoV-2 Spike-ACE2 interaction. Among these, PoMA-10, featuring trifluoromethoxy and dimethylaniline moieties, exhibited the most potent inhibitory activity while preserving ACE2 enzymatic function. Computational modeling predicted direct binding of PoMA-10 to ACE2, which was corroborated by protein mobility shift assays. This was further substantiated by surface plasmon resonance analysis and molecular dynamics simulations, which confirmed the stable binding of PoMA-10 at an interface-adjacent site on ACE2 and the disruption of SARS-CoV-2 Spike–ACE2 interaction. In Vero cells, PoMA-10 significantly reduced infection by ancestral SARS-CoV-2 and the Delta and Gamma variants. Moreover, PoMA-10 alleviated lung epithelial cell damage and protected against lipopolysaccharide-induced lung injury in vivo . These findings demonstrate that PoMA-10 functions as a dual-action inhibitor blocking viral entry and protecting against lung injury, and highlight its potential as a therapeutic candidate in the management of COVID-19 and related pulmonary complications.
- Open Access
- 30 March 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (2) , e13790
Transcriptional Co‐Activator With PDZ Binding Motif (TAZ) Inhibits Dexamethasone‐Induced Muscle Atrophy via mTOR Signalling
Background: Glucocorticoid therapy has a beneficial effect in several diseases, but chronic treatment has adverse effects, including muscle atrophy, which refers to the gradual decrease in muscle mass, size and strength. It is important to know how the muscle atrophy occurs, but the underlying mechanism is not yet fully understood. This study shows that dexamethasone decreases levels of the transcriptional co‐activator with PDZ binding motif (TAZ), which facilitates dexamethasone‐induced muscle atrophy. Methods: To induce muscle atrophy, C2C12 myotubes were treated with dexamethasone, and mice were fed with water containing dexamethasone. Muscle atrophy was analysed for the expression of myosin heavy chain, MuRF1 and Atrogin‐1 using immunofluorescence staining, immunoblot analysis and qRT‐PCR. Muscle tissue was analysed by haematoxylin and eosin staining. Adeno‐associated virus was used for overexpression of wild‐type and mutant TAZ. Results: TAZ levels decrease in dexamethasone‐treated mice (0.36‐fold, p < 0.001) and C2C12 myotubes (0.44‐fold, p = 0.024). Overexpression of the TAZ mutant, which resists its proteolytic degradation, inhibits dexamethasone‐induced muscle atrophy. Atrogin‐1 and MuRF1 interact with TAZ and facilitate its degradation in dexamethasone‐treated C2C12 myotubes. TAZ mutant stimulates protein synthesis through activation of mTOR signalling via induction of RhebL1 (DEX; Con vs, TAZ4SA: 5.1‐fold, p < 0.001) in dexamethasone‐treated mice. Ginsenoside Rb3 increases TAZ levels in dexamethasone‐treated mice (1.49‐fold, p = 0.007) and C2C12 myotubes (1.63‐fold, p = 0.01), which stimulates mTOR signalling and inhibits dexamethasone‐induced muscle atrophy. Conclusions: Our results demonstrate a novel regulatory mechanism of dexamethasone‐induced muscle atrophy by TAZ, suggesting that stabilisation of TAZ in muscle cells ameliorates the muscle atrophy. These results suggest that TAZ may be a drug target for the dexamethasone‐induced muscle atrophy.
- 30 March 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (2) , e13790
Open AccessTranscriptional Co‐Activator With PDZ Binding Motif (TAZ) Inhibits Dexamethasone‐Induced Muscle Atrophy via mTOR Signalling
Background: Glucocorticoid therapy has a beneficial effect in several diseases, but chronic treatment has adverse effects, including muscle atrophy, which refers to the gradual decrease in muscle mass, size and strength. It is important to know how the muscle atrophy occurs, but the underlying mechanism is not yet fully understood. This study shows that dexamethasone decreases levels of the transcriptional co‐activator with PDZ binding motif (TAZ), which facilitates dexamethasone‐induced muscle atrophy. Methods: To induce muscle atrophy, C2C12 myotubes were treated with dexamethasone, and mice were fed with water containing dexamethasone. Muscle atrophy was analysed for the expression of myosin heavy chain, MuRF1 and Atrogin‐1 using immunofluorescence staining, immunoblot analysis and qRT‐PCR. Muscle tissue was analysed by haematoxylin and eosin staining. Adeno‐associated virus was used for overexpression of wild‐type and mutant TAZ. Results: TAZ levels decrease in dexamethasone‐treated mice (0.36‐fold, p < 0.001) and C2C12 myotubes (0.44‐fold, p = 0.024). Overexpression of the TAZ mutant, which resists its proteolytic degradation, inhibits dexamethasone‐induced muscle atrophy. Atrogin‐1 and MuRF1 interact with TAZ and facilitate its degradation in dexamethasone‐treated C2C12 myotubes. TAZ mutant stimulates protein synthesis through activation of mTOR signalling via induction of RhebL1 (DEX; Con vs, TAZ4SA: 5.1‐fold, p < 0.001) in dexamethasone‐treated mice. Ginsenoside Rb3 increases TAZ levels in dexamethasone‐treated mice (1.49‐fold, p = 0.007) and C2C12 myotubes (1.63‐fold, p = 0.01), which stimulates mTOR signalling and inhibits dexamethasone‐induced muscle atrophy. Conclusions: Our results demonstrate a novel regulatory mechanism of dexamethasone‐induced muscle atrophy by TAZ, suggesting that stabilisation of TAZ in muscle cells ameliorates the muscle atrophy. These results suggest that TAZ may be a drug target for the dexamethasone‐induced muscle atrophy.
- Open Access
- 14 January 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 183, 117856
SMEPPI: An indenone derivative that selectively inhibits M1 macrophage activation and enhances phagocytic activity
- 14 January 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 183, 117856
Open AccessSMEPPI: An indenone derivative that selectively inhibits M1 macrophage activation and enhances phagocytic activity
- Open Access
- 11 May 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-12
TAZ deficiency exacerbates psoriatic pathogenesis by increasing the histamine-releasing factor
Background: Transcriptional coactivator with PDZ-biding motif (TAZ) is widely expressed in most tissues and interacts with several transcription factors to regulate cell proliferation, differentiation, and death, thereby influencing organ development and size control. However, very little is known about the function of TAZ in the immune system and its association with inflammatory skin diseases, so we investigated the role of TAZ in the pathogenesis of psoriasis. Results: Interestingly, TAZ was expressed in mast cells associated, particularly in lysosomes, and co-localized with histamine-releasing factor (HRF). TAZ deficiency promoted mast cell maturation and increased HRF expression and secretion by mast cells. The upregulation of HRF in TAZ deficiency was not due to increased transcription but to protein stabilization, and TAZ restoration into TAZ-deficient cells reduced HRF protein. Interestingly, imiquimod (IMQ)-induced psoriasis, in which HRF serves as a major pro-inflammatory factor, was more severe in TAZ KO mice than in WT control. HRF expression and secretion were increased by IMQ treatment and were more pronounced in TAZ KO mice treated with IMQ. Conclusions: Thus, as HRF expression was stabilized in TAZ KO mice, psoriatic pathogenesis progressed more rapidly, indicating that TAZ plays an important role in preventing psoriasis by regulating HRF protein stability. Graphical
- 11 May 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-12
Open AccessTAZ deficiency exacerbates psoriatic pathogenesis by increasing the histamine-releasing factor
Background: Transcriptional coactivator with PDZ-biding motif (TAZ) is widely expressed in most tissues and interacts with several transcription factors to regulate cell proliferation, differentiation, and death, thereby influencing organ development and size control. However, very little is known about the function of TAZ in the immune system and its association with inflammatory skin diseases, so we investigated the role of TAZ in the pathogenesis of psoriasis. Results: Interestingly, TAZ was expressed in mast cells associated, particularly in lysosomes, and co-localized with histamine-releasing factor (HRF). TAZ deficiency promoted mast cell maturation and increased HRF expression and secretion by mast cells. The upregulation of HRF in TAZ deficiency was not due to increased transcription but to protein stabilization, and TAZ restoration into TAZ-deficient cells reduced HRF protein. Interestingly, imiquimod (IMQ)-induced psoriasis, in which HRF serves as a major pro-inflammatory factor, was more severe in TAZ KO mice than in WT control. HRF expression and secretion were increased by IMQ treatment and were more pronounced in TAZ KO mice treated with IMQ. Conclusions: Thus, as HRF expression was stabilized in TAZ KO mice, psoriatic pathogenesis progressed more rapidly, indicating that TAZ plays an important role in preventing psoriasis by regulating HRF protein stability. Graphical
- Open Access
- 4 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116674
MPoMA protects against lung epithelial cell injury via p65 degradation
- 4 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116674
Open AccessMPoMA protects against lung epithelial cell injury via p65 degradation
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (7) , 2592-2606
TAZ deficiency impairs the autophagy-lysosomal pathway through NRF2 dysregulation and lysosomal dysfunction
Transcriptional coactivator with a PDZ-binding motif (TAZ) plays a key role in normal tissue homeostasis and tumorigenesis through interaction with several transcription factors. In particular, TAZ deficiency causes abnormal alveolarization and emphysema, and persistent TAZ overexpression contributes to lung cancer and pulmonary fibrosis, suggesting the possibility of a complex mechanism of TAZ function. Recent studies suggest that nuclear factor erythroid 2-related factor 2 (NRF2), an antioxidant defense system, induces TAZ expression during tumorigenesis and that TAZ also activates the NRF2-mediated antioxidant pathway. We thus thought to elucidate the cross-regulation of TAZ and NRF2 and the underlying molecular mechanisms and functions. TAZ directly interacted with NRF2 through the N-terminal domain and suppressed the transcriptional activity of NRF2 by preventing NRF2 from binding to DNA. In addition, the return of NRF2 to basal levels after signaling was inhibited in TAZ deficiency, resulting in sustained nuclear NRF2 levels and aberrantly increased expression of NRF2 targets. TAZ deficiency failed to modulate optimal NRF2 signaling and concomitantly impaired lysosomal acidification and lysosomal enzyme function, accumulating the abnormal autophagy vesicles and reactive oxygen species and causing protein oxidation and cellular damage in the lungs. TAZ restoration to TAZ deficiency normalized dysregulated NRF2 signaling and aberrant lysosomal function and triggered the normal autophagy-lysosomal pathway. Therefore, TAZ is indispensable for the optimal regulation of NRF2-mediated autophagy-lysosomal pathways and for preventing pulmonary damage caused by oxidative stress and oxidized proteins.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (7) , 2592-2606
Open AccessTAZ deficiency impairs the autophagy-lysosomal pathway through NRF2 dysregulation and lysosomal dysfunction
Transcriptional coactivator with a PDZ-binding motif (TAZ) plays a key role in normal tissue homeostasis and tumorigenesis through interaction with several transcription factors. In particular, TAZ deficiency causes abnormal alveolarization and emphysema, and persistent TAZ overexpression contributes to lung cancer and pulmonary fibrosis, suggesting the possibility of a complex mechanism of TAZ function. Recent studies suggest that nuclear factor erythroid 2-related factor 2 (NRF2), an antioxidant defense system, induces TAZ expression during tumorigenesis and that TAZ also activates the NRF2-mediated antioxidant pathway. We thus thought to elucidate the cross-regulation of TAZ and NRF2 and the underlying molecular mechanisms and functions. TAZ directly interacted with NRF2 through the N-terminal domain and suppressed the transcriptional activity of NRF2 by preventing NRF2 from binding to DNA. In addition, the return of NRF2 to basal levels after signaling was inhibited in TAZ deficiency, resulting in sustained nuclear NRF2 levels and aberrantly increased expression of NRF2 targets. TAZ deficiency failed to modulate optimal NRF2 signaling and concomitantly impaired lysosomal acidification and lysosomal enzyme function, accumulating the abnormal autophagy vesicles and reactive oxygen species and causing protein oxidation and cellular damage in the lungs. TAZ restoration to TAZ deficiency normalized dysregulated NRF2 signaling and aberrant lysosomal function and triggered the normal autophagy-lysosomal pathway. Therefore, TAZ is indispensable for the optimal regulation of NRF2-mediated autophagy-lysosomal pathways and for preventing pulmonary damage caused by oxidative stress and oxidized proteins.
- Open Access
- 3 November 2023
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 14 (6) , 2733-2746
TAZ stimulates exercise‐induced muscle satellite cell activation via Pard3–p38 MAPK–TAZ signalling axis
Background: Exercise stimulates the activation of muscle satellite cells, which facilitate the maintenance of stem cells and their myogenic conversion during muscle regeneration. However, the underlying mechanism is not yet fully understood. This study shows that the transcriptional co‐activator with PDZ‐binding motif (TAZ) stimulates muscle regeneration via satellite cell activation.Methods: Tazf/f mice were crossed with the paired box gene 7 (Pax7)creERT2 mice to generate muscle satellite cell‐specific TAZ knockout (sKO) mice. Mice were trained in an endurance exercise programme for 4 weeks. Regenerated muscles were harvested and analysed by haematoxylin and eosin staining. Muscle tissues were also analysed by immunofluorescence staining, immunoblot analysis and quantitative reverse transcription PCR (qRT‐PCR). For the in vitro study, muscle satellite cells from wild‐type and sKO mice were isolated and analysed. Mitochondrial DNA was quantified by qRT‐PCR using primers that amplify the cyclooxygenase‐2 region of mitochondrial DNA. Quiescent and activated satellite cells were stained with MitoTracker Red CMXRos to analyse mitochondria. To study the p38 mitogen‐activated protein kinase (MAPK)–TAZ signalling axis, p38 MAPK was activated by introducing the MAPK kinase 6 plasmid into satellite cells and also inhibited by treatment with the p38 MAPK inhibitor, SB203580.Results: TAZ interacts with Pax7 to induce Myf5 expression and stimulates mammalian target of rapamycin signalling for satellite cell activation. In sKO mice, TAZ depletion reduces muscle satellite cell number by 38% (0.29 ± 0.073 vs. 0.18 ± 0.034, P = 0.0082) and muscle regeneration. After muscle injury, TAZ levels (2.59‐fold, P < 0.0001) increase in committed cells compared to self‐renewing cells during asymmetric satellite cell division. Mechanistically, the polarity protein Pard3 induces TAZ (2.01‐fold, P = 0.008) through p38 MAPK, demonstrating that the p38 MAPK–TAZ axis is important for muscle regeneration. Physiologically, endurance exercise training induces muscle satellite cell activation and increases muscle fibre diameter (1.33‐fold, 43.21 ± 23.59 vs. 57.68 ± 23.26 μm, P = 0.0004) with increased TAZ levels (1.76‐fold, P = 0.017). However, sKO mice had a 39% reduction in muscle satellite cell number (0.20 ± 0.03 vs. 0.12 ± 0.02, P = 0.0013) and 24% reduction in muscle fibre diameter compared to wild‐type mice (61.07 ± 23.33 vs. 46.60 ± 24.29 μm, P = 0.0006).Conclusions: Our results demonstrate a novel mechanism of TAZ‐induced satellite cell activation after muscle injury and exercise, suggesting that activation of TAZ in satellite cells may ameliorate the muscle ageing phenotype and may be an important target protein for the drug development in sarcopenia.
- 3 November 2023
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 14 (6) , 2733-2746
Open AccessTAZ stimulates exercise‐induced muscle satellite cell activation via Pard3–p38 MAPK–TAZ signalling axis
Background: Exercise stimulates the activation of muscle satellite cells, which facilitate the maintenance of stem cells and their myogenic conversion during muscle regeneration. However, the underlying mechanism is not yet fully understood. This study shows that the transcriptional co‐activator with PDZ‐binding motif (TAZ) stimulates muscle regeneration via satellite cell activation.Methods: Tazf/f mice were crossed with the paired box gene 7 (Pax7)creERT2 mice to generate muscle satellite cell‐specific TAZ knockout (sKO) mice. Mice were trained in an endurance exercise programme for 4 weeks. Regenerated muscles were harvested and analysed by haematoxylin and eosin staining. Muscle tissues were also analysed by immunofluorescence staining, immunoblot analysis and quantitative reverse transcription PCR (qRT‐PCR). For the in vitro study, muscle satellite cells from wild‐type and sKO mice were isolated and analysed. Mitochondrial DNA was quantified by qRT‐PCR using primers that amplify the cyclooxygenase‐2 region of mitochondrial DNA. Quiescent and activated satellite cells were stained with MitoTracker Red CMXRos to analyse mitochondria. To study the p38 mitogen‐activated protein kinase (MAPK)–TAZ signalling axis, p38 MAPK was activated by introducing the MAPK kinase 6 plasmid into satellite cells and also inhibited by treatment with the p38 MAPK inhibitor, SB203580.Results: TAZ interacts with Pax7 to induce Myf5 expression and stimulates mammalian target of rapamycin signalling for satellite cell activation. In sKO mice, TAZ depletion reduces muscle satellite cell number by 38% (0.29 ± 0.073 vs. 0.18 ± 0.034, P = 0.0082) and muscle regeneration. After muscle injury, TAZ levels (2.59‐fold, P < 0.0001) increase in committed cells compared to self‐renewing cells during asymmetric satellite cell division. Mechanistically, the polarity protein Pard3 induces TAZ (2.01‐fold, P = 0.008) through p38 MAPK, demonstrating that the p38 MAPK–TAZ axis is important for muscle regeneration. Physiologically, endurance exercise training induces muscle satellite cell activation and increases muscle fibre diameter (1.33‐fold, 43.21 ± 23.59 vs. 57.68 ± 23.26 μm, P = 0.0004) with increased TAZ levels (1.76‐fold, P = 0.017). However, sKO mice had a 39% reduction in muscle satellite cell number (0.20 ± 0.03 vs. 0.12 ± 0.02, P = 0.0013) and 24% reduction in muscle fibre diameter compared to wild‐type mice (61.07 ± 23.33 vs. 46.60 ± 24.29 μm, P = 0.0006).Conclusions: Our results demonstrate a novel mechanism of TAZ‐induced satellite cell activation after muscle injury and exercise, suggesting that activation of TAZ in satellite cells may ameliorate the muscle ageing phenotype and may be an important target protein for the drug development in sarcopenia.
- Open Access
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (12) , 4182-4196
Endothelial TAZ inhibits capillarization of liver sinusoidal endothelium and damage-induced liver fibrosis via nitric oxide production
Background: Endothelial dysfunction is a systemic disorder and is involved in the pathogenesis of several human diseases. Hemodynamic shear stress plays an important role in vascular homeostasis including nitric oxide (NO) production. Impairment of NO production in endothelial cells stimulates the capillarization of liver sinusoidal endothelial cells, followed by hepatic stellate cell activation, inducing liver fibrosis. However, the detailed mechanism underlying NO production is not well understood. In hepatocytes, transcriptional co-activator with PDZ-binding motif (TAZ) has been reported to be involved in liver fibrosis. However, the role of endothelial TAZ in liver fibrosis has not been investigated. In this study, we uncovered the role TAZ in endothelial cell NO production, and its subsequent effects on liver fibrosis.
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (12) , 4182-4196
Open AccessEndothelial TAZ inhibits capillarization of liver sinusoidal endothelium and damage-induced liver fibrosis via nitric oxide production
Background: Endothelial dysfunction is a systemic disorder and is involved in the pathogenesis of several human diseases. Hemodynamic shear stress plays an important role in vascular homeostasis including nitric oxide (NO) production. Impairment of NO production in endothelial cells stimulates the capillarization of liver sinusoidal endothelial cells, followed by hepatic stellate cell activation, inducing liver fibrosis. However, the detailed mechanism underlying NO production is not well understood. In hepatocytes, transcriptional co-activator with PDZ-binding motif (TAZ) has been reported to be involved in liver fibrosis. However, the role of endothelial TAZ in liver fibrosis has not been investigated. In this study, we uncovered the role TAZ in endothelial cell NO production, and its subsequent effects on liver fibrosis.
- Open Access
- 8 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 152, 113245
Dimeric translationally controlled tumor protein–binding peptide 2 attenuates imiquimod-induced psoriatic inflammation through induction of regulatory T cells
- 8 June 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 152, 113245
Open AccessDimeric translationally controlled tumor protein–binding peptide 2 attenuates imiquimod-induced psoriatic inflammation through induction of regulatory T cells